PD59: Kidney Cancer: Advanced (including Drug Therapy) II

Podium Session Moderator(s)

• 

  Stephen Boorjian, MD

  Professor of Urology
  Mayo Clinic
• 

  Casey Ng, MD

  Southern California Permanente Medical Group
• 

  Alessandro Larcher, MD

Presentations:

• 1:00 PM – 1:10 PM

  PD59-01: BAP1 Loss is Associated with Metastasis in Advanced Clear Cell Renal Cell Carcinoma
  

  Podium Presenter: Sari S. Khaleel, MD, MSC – Memorial Sloan Kettering Cancer Center
• 1:10 PM – 1:20 PM

  PD59-02: Prostate Specific Membrane Antigen Expression is Associated with Angiogenesis and Tyrosine Kinase Inhibitor Response in Clear cell Renal Cell Carcinoma
  

  Podium Presenter: Sari S. Khaleel, MD, MSC – Memorial Sloan Kettering Cancer Center
• 1:20 PM – 1:30 PM

  PD59-03: Adjuvant Therapy After Surgical Resection of Nonmetastatic Renal-Cell Carcinoma: one size does not fit all
  

  Podium Presenter: Zine-Eddine KHENE
• 1:30 PM – 1:40 PM

  PD59-04: Application of the KEYNOTE-564 trial results to real life population: which patients with advanced kidney cancer should receive adjuvant pembrolizumab
  

  Podium Presenter: Giuseppe Fallara, MD
• 1:40 PM – 1:50 PM

  PD59-05: Cost Effectiveness of adjuvant pembrolizumab after nephrectomy for RCC: insights for patient selection from a Markov Model
  

  Podium Presenter: Vidit Sharma, MD,MS
• 1:50 PM – 2:00 PM

  PD59-06: Pembrolizumab outperforms tyrosine kinase inhibitors in the adjuvant therapy of patients with high-risk renal cell carcinoma: a systematic review and network meta-analysis
  

  Podium Presenter: Ekaterina Laukhtina
• 2:00 PM – 2:10 PM

  PD59-07: Neglected lymph nodal metastases in patients with renal cancer: when to extend the anatomical template of lymph node dissection during nephrectomy
  

  Podium Presenter: Giuseppe Rosiello, MD – San Raffaele Hospital
• 2:10 PM – 2:20 PM

  PD59-08: International Multi-Institutional Characterization of the Perioperative Morbidity of Metastasectomy for Renal Cell Carcinoma
  

  Podium Presenter: Timothy D. Lyon, MD
• 2:20 PM – 2:30 PM

  PD59-09: Outcomes of Cytoreductive Nephrectomy Followed by Active Surveillance in Metastatic Renal Cell Carcinoma
  

  Podium Presenter: Sari S. Khaleel, MD, MSC – Memorial Sloan Kettering Cancer Center
• 2:30 PM – 2:40 PM

  PD59-10: Improving Decision-Making for Cytoreductive Nephrectomy by Evaluating Pre-Surgical Radiographic Tumor Characteristics
  

  Podium Presenter: Daniel Shapiro, MD
• 2:40 PM – 2:50 PM

  PD59-11: Association between immune-related adverse events and clinical outcomes in advanced genitourinary cancers treated with immunotherapy: a systematic review and meta-analysis
  

  Podium Presenter: Junru Chen
• 2:50 PM – 3:00 PM

  PD59-12: Microwave Ablation Combined with Anti-PD-1/CTLA-4 Therapy Induces Anti-Tumor Immune Response to Renal Cell Carcinoma in a Murine Model
  

  Podium Presenter: Run-Qi GUO, MD – Beijing Hospital